GERMINAÇÃO DE SEMENTES DE Piptadenia moniliformis Benth. SOB ESTRESSE HÍDRICO

O período de germinação e o estabelecimento de plântulas é um dos fatores mais importantes para a sobrevivência das espécies, principalmente nos locais em que a disponibilidade de água é limitada, como na região da Caatinga. Neste sentido, o objetivo deste trabalho foi avaliar o efeito do estresse hídrico sobre a germinação de sementes de Piptadenia moniliformis Benth. Foram utilizados três lotes (L1, L2 e L3), correspondentes aos anos de produção de 2006, 2007 e 2008, respectivamente. Antes do teste de germinação, as sementes foram escarificadas com ácido sulfúrico concentrado durante 30 minutos. Para induzir o deficit hídrico, foi utilizado o polietileno glicol (PEG 6000), nos seguintes potenciais osmóticos: - 0,3; -0,6; -0,9, -1,2 e -1,5 MPa e a água (0 MPa) sob as temperaturas de 25 e 30ºC. As características avaliadas foram: porcentagem de germinação e de plântulas normais, índice de velocidade de germinação e massa seca de plântulas. O processo germinativo de sementes de Piptadenia moniliformis Benth. é comprometido a partir de potenciais hídricos inferiores a -0,6 MPa a 25 e 30 °C; potenciais hídricos iguais ou inferiores a -1,2 MPa inibem a formação de plântulas normais nas duas temperaturas; a tolerância ao estresse hídrico simulado com PEG 6000 é variável entre lotes de sementes e temperaturas de germinação.

Flixweed vs. Polyethylene Glycol in the Treatment of Childhood Functional Constipation: A Randomized Clinical Trial

Background: Polyethylene glycol (PEG) is often considered as the first-line treatment for functional constipation in children. Descurainia sophia (L.) Webb et Berth (D. sophia) is a safe recommended medicine in Iranian folk and Traditional Persian Medicine for the treatment of constipation. Objectives: To clinically compare D. sophia with PEG 4000 (without electrolyte) in pediatric constipation and to assess its efficacy and side effects. Patients and Methods: 120 patients aged 2 - 12 years with constipation for at least 3 months were included in an 8 weeks lasting randomized controlled trial within two parallel-groups. Children received either PEG, 0.4 g/kg/day, or D. sophia seeds, 2 grams (for children aged 2 - 4 years) and 3 grams (for those aged > 4 years) per day. Results: A total of 109 patients completed the study (56 in D. sophia and 53 in PEG group). At the end of the study, 36 (64.3%) patients in D. sophia group and 29 (54.7%) in PEG group were out of Rome III criteria (P = 0.205). Median weekly stool frequency in 0, 1, 2, 3 weeks of the treatment was found to be 2, 5, 5, 5 in D. sophia and 3, 4, 4, 5 in PEG group (P = 0.139, 0.076, 0.844, 0.294), respectively. The number of patients who suffered flatulence was less (5, 8.9%) in D. sophia group as compared to PEG group (6, 11.3%) at the end of the trial (P = 0.461). D. sophia taste was less tolerated. Conclusions: D. sophia is introduced as a cheap and available medication which can be applied as a safe alternative to conventional PEG in the management of pediatric chronic functional constipation.

Dissolution rate enhancement of repaglinide by solid dispersion

Purpose: To enhance the solubility and dissolution rate of the antidiabetic drug repaglinide by solid dispersion (SD) technique Method: The solid dispersion of repaglinide was prepared by solvent evaporation method using the hydrophilic carrier, polyethylene glycol 4000 (PEG 4000) in three drug:PEG 4000 ratios (1:1, 1:3, 1:5). For comparison, physical mixtures of repaglinide and PEG 4000 in the same ratios were also prepared. The formulations were characterized by Fourier transformed infrared spectroscopy (FTIR), x-ray diffractometry (XRD) and differential scanning colorimetry (DSC). Phase solubility study of pure repaglinide, physical mixture and solid dispersion was performed in distilled water. Dissolution studies were carried out in pH 7.4 phosphate buffer. Results: DSC and XRD results indicate that repaglinide exists in amorphous form in solid dispersion. FT-IR analysis demonstrated the presence of intermolecular hydrogen bonding between repaglinide and PEG 4000 in the solid dispersion. The solubility of pure repaglinide was enhanced from 22.5± 5.0 to 235.5± 5.0 µg/mL in distilled water at 37 0C. Rapid burst release (80 - 86 %) from the solid dispersion formulations was observed within 15 min. Conclusion: The solubility and dissolution rate of repaglinide are enhanced by formulating SDs of repaglinide with PEG 4000. This will likely lead to increase in bioavailability which would be beneficial for better glucose control in diabetic patients.